Nebenwirkungen · Gobivaz
GOBIVAZ 50 mg solution for injection in pre-filled pen. · Abschnitt 4.8 · PDF-Seite 44
HOS-153519 · Präparat HOS-101000
In the controlled period of pivotal trials, infections were observed in 23.0% of golimumab-treated patients (incidence per 100 subject-years: 132.0; 95% CI: 123.3, 141.1) compared with 20.2% of control patients (incidence per 100 subject-years: 122.3; 95% CI: 109.5, 136.2). In controlled and uncontrolled portions of the trials with a median follow-up of approximately 4 years, the incidence per 100 subject-years of infections was 81.1 events; 95% CI: 79.5, 82.8 for golimumab treated patients.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T10:38:00Z · SHA-256 b368a4f3ae6dce5887430617ccfcdc36900996af800ff08514415b29e19f2102 · Passage 6e1ebe18c60aafcbbd67ff20cdf9229a32e3bf552bf2bfacaa826375c6ac94d3 · Zeichen 7981–8477 im Abschnitt